Hetero Labs Ltd. has patented benzimidazole compounds acting as EGFR (HER1; erbB1) and its mutant inhibitors. They are reported to be useful for the treatment of cancer.

Helmholtz Zentrum Fur Infektionsforschung GmbH has reported argyrin derivatives designed for potential use for the treatment of Neisseria gonorrhoeae and Clostridioides difficile infections.

U.S. Department of Health and Human Services (HHS) has discovered dopamine D2 receptor antagonists potentially useful for the treatment of Tourette disease, bipolar disorder, tardive dyskinesia, Huntington’s disease, schizophrenia, depression, postoperative nausea and vomiting and gastroesophageal reflux disease.

Avicenna Biosciences Inc. has reported Rho kinase (ROCK) inhibitors described as potentially useful for the treatment of cancer, fibrosis, neurodegeneration, overactive bladder, scleroderma, diabetic retinopathy, traumatic brain injury and renal disorders, among others.

China Pharmaceutical University, Jiangsu Deyuan Pharmaceutical Co. Ltd. and Nanjing Deyuan Pharmaceutical Co. Ltd. have disclosed glucagon-like peptide-1 receptor (GLP-1R) agonists.

Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, glaucoma, inflammatory bowel disease, multiple sclerosis, neurodegeneration, psoriasis and rheumatoid arthritis, among others.

Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.

Acerand Therapeutics (Hong Kong) Ltd. has divulged new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.

Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.

Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).